Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease

US5756449A · kind A · utility

Assignees

• Peptide Technology Ltd. · AU
• Drug Royalty Corporation · AU

Inventors

• Anders Jorgen Andersen · Kokkedal, DK
• Roger Aston · Gloucester, GB
• Peter Louis Carlen · Schreiber, CA
• Penelope Reed Doob · Schreiber, CA
• Douglas Kevin MacFadden · Schreiber, CA
• David James Phipps · Toronto, CA
• Deborah Rathjen · Forbes, AU
• Fred Widmer · Forbes, AU

Key dates

• Filing date: Feb 24, 1995
• Grant date: May 26, 1998
• Expiry date: Feb 24, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16122
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating inflammatory bowel disease in patients in need of such treatment by administering an effective amount of: I-A-B-C-D-E-F-G-H-II (General Formula I), wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr, or absent, C is Ser, Thr or absent. D is Ser, Thr, Asn, Glu, Arg, IIe, Leu or absent, E is Ser, Thr, Asp or absent, F is Ser, Thr, Asp or absent, G is Tyr or absent, H is Thr, Arg, Gly, Met, Met(O), Cys, Thr, Gly or absent, and I is Cys or absent II is Cys, an amide group, substituted amid group, an ester group or absent. At least one of the amino acids optionally being substituted by a monomeric or polymeric carbohydrate or derivative thereof, such substitution being accomplished through hydroxyl and/or amino and/or amido groups of the amino acids, and wherein the peptide comprises at least 4 amino acid residues, and a pharmaceutically acceptable salt thereof.